



# SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.  
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

**Ref: SPL/CORP-SEC/2019-20/BSE/1079**

**Dated: 13.08.2019**

To,  
Bombay Stock Exchange Ltd,  
Phirojshah Jeejobhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

**Sub: Outcome of the Board Meeting for the FY 2019-20 held on Tuesday, 13<sup>th</sup> August 2019 with Scrip Code 524703.**

A Meeting of the Board of Directors of the Company duly convened on **Tuesday, 13<sup>th</sup> August 2019 at 5:00 p.m. and Concluded at 5.50 p.m.** at the Registered Office of the Company at Sandu Pharmaceuticals Limited, Plot No 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez Goa 403511 inter alia, discussed the following business:-

1. It has approved Unaudited Financial Results for the Quarter ended 30<sup>th</sup> June 2019 along with Limited Review Report.
2. It has approved Reappointment of Swapnil J Dixit & Associates as Secretarial Auditor of the Company for the Financial year 2019-20 .
3. Based on Recommendation made by Nomination and Remuneration Committee, Board has approved Appointment of Shri Bhaskar G Sandu (DIN:02816792) as Additional Director. The Requisite disclosure in term of Regulation 30 of the SEBI (Listing Disclosure and Requirement) Regulation 2015 to the extend applicable to appointment is given under the Annexure A.
4. Based on the Recommendation made by Nomination and Remuneration Committee, Board has approved Continuation of below mentioned Directors on the Board, on attaining the age of 75 years subjected to the approval of the shareholder in forthcoming Annual General Meeting. The Requisite disclosure in term of Regulation 30 of the SEBI (Listing Disclosure and Requirement) Regulation 2015 to the extend applicable to appointment is given under the Annexure A.

a) Dr Krishna Deshpande (DIN:06557518), Non Executive Independent Director

b) Dr Shubhada Sandu (DIN:07148834), Non Executive Non Independent Director



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.  
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587





# SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.  
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

## ANNEXURE A:

Name of the Director	Dr Shubhada G Sandu	Dr Krishna Deshpande	Shri Bhaskar Sandu
Qualifications	B.A.M.S.	M.B.B.S, D.L.O,F.R.C.S.	BCOM
Expertise in specific functional area	Dr. Mrs. Shubhada P Sandu (DIN:07148834) is the practicing Ayurvedic Doctor and has obtained B.A.M.S. degree from the University of Mumbai. She has vast and rich experience in Ayurvedic Practice, Ayurvedic formulation and manufacturing.	Dr Krishna B deshpande (DIN:06557518) is a Bachelor of Medicine and Surgrey(M.B.B.S) from Aurangabad Medical College. He is also a member (fellowship) of American Board of Surgeons, Royal College of Surgeons and Surgical Association of Gastrointestinal Endopic Surgery.He has more than 45 years of experience in the medical field and has worked at various senior positions.He is currently attached with Hospitals in Cleveland Ohio,USA	Shri Bhaskar Sandu (DIN:02816792) has vast experience in Ayurvedic, Extraction, formulations, manufacturing and Finance. He possesses more than 50 years of working experience in the Ayurvedic Industry.
Disclosure of Relationship with Directors	Relative of Director	Not Related	Relative of Director



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.  
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587





## SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.  
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

You are requested to kindly take the same on record.

Thanking You

Yours Faithfully

For Sandu Pharmaceuticals Limited



Company Secretary



### AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.  
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN: L24233GA1985PLC001587





# SANDU PHARMACEUTICALS LTD

**Corporate Office:** P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.  
Tel : +91 22 25284402/3306, Fax: +91 22 25282403, E-mail: info@sandu.in, Web: www.sandu.in

**Sandu Pharmaceuticals Ltd**

**STATEMENT OF UNAUDITED RESULTS FOR THE PERIOD ENDED 30/06/19**

					(Rs in Lakhs)
	Particulars	Qtr Ending June 2019 (Un audited)	Qtr Ending March 2019 (Audited)	Qtr Ending June 2018 (Un Audited)	Year Ended March 2019 (Audited)
I	Revenue From Operations	1,234.53	1,192.04	1,110.86	4,942.46
II	Other Income	14.42	14.01	19.40	57.40
III	Total Income (I+II)	1,248.95	1,206.05	1,130.26	4,999.86
IV	<b>EXPENSES</b>				
	Cost of materials consumed	179.63	279.24	167.49	854.88
	Purchases of Stock-in-Trade	363.99	512.10	583.09	1,833.24
	Changes in inventories of finished goods,	173.26	(247.34)	(200.47)	(156.90)
	Employee benefits expense	147.27	118.35	172.93	652.38
	Finance costs	13.73	19.08	25.42	101.18
	Depreciation and amortization expense	13.60	15.68	15.78	63.58
	Other expenses	330.60	491.63	330.55	1,549.47
	<b>Total expenses (IV)</b>	<b>1,222.08</b>	<b>1,188.74</b>	<b>1,094.79</b>	<b>4,897.83</b>
V	Profit/(loss) before exceptional items and tax (I-	26.87	17.31	35.47	102.03
VI	Exceptional Items			-	0.26
VII	Profit/(loss) before tax (V-VI)	26.87	17.31	35.47	101.77
	Tax expense:				
VIII	(1) Current tax	6.98	14.64	9.13	36.50
	(2) Deferred tax	3.70	0.94	(6.11)	(1.64)
	Short / ( Excess ) Tax Provision	(14.80)	-	-	-
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	30.99	1.73	32.45	66.91
X	Profit/(loss) for the period (IX+XII)	30.99	1.73	32.45	66.91
XI	Other Comprehensive Income				
	A (i) Items that will not be reclassified to profit or loss		(0.94)	(1.63)	4.67
	a. Remeasurement gains/(losses) on post employment defined benefit plans				
	b. Fair value changes of investments	6.14	-	-	0.30
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.63)	-	(0.16)	(1.25)
	B (i) Items that will be reclassified to profit or loss				
	(ii) Income tax relating to items that will be reclassified to profit or loss				
	Total Comprehensive Income for the period (X+XI)(Comprising Profit	36.50	0.79	30.66	70.63
XII	(Loss) and Other Comprehensive Income for the period)				
XIII	Paid Up Equity Capital ( Face Value of Rs 10/- Per share )	708.10	708.10	708.10	708.10
XIV	Earnings per equity share (for continuing operation):				
	(1) Basic	0.44	0.02	0.46	0.94
	(2) Diluted				

Place: Mumbai  
Date: 13/08/2019




For Sandu Pharmaceuticals Limited

Umesh Sandu  
(Managing Director)  
DIN: 01132141




1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 13<sup>th</sup> August, 2019. The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
3. The Figures for the quarter ended 31 st March, 2019 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.
4. Figures for the previous periods have been reclassified/regrouped, whenever necessary

Date: - 13/08/2019



For Sandu Pharmaceuticals Ltd

  
Umesh Sandu  
(Managing Director)  
DIN: 01132141





# Dileep & Prithvi

CHARTERED ACCOUNTANTS

## "LIMITED REVIEW" REPORT ON THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER

ENDED ON 30TH JUNE, 2019

To,

The Board of Directors,  
Sandu Pharmaceuticals Limited,  
Plot No. 25, 26, 29 & 30,  
Pilerne Industrial Estate, Marra,  
Bardez, Goa-403511.

Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter ended June 30, 2019, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Dileep & Prithvi**

Chartered Accountants

Firm Registration Number : 122290W

*Himmat Mali*

**Himmat Mali**

(Partner)

Membership Number : 183378

UDIN-19183378AAAAAG1762



Place: Mumbai  
Date: 13<sup>th</sup> August, 2019

### HEAD OFFICE :

4-A, 3rd Floor, Dahanukar Bldg., 480, Kalbadevi Road,  
Mumbai - 400 002. • Tel.: +91-22-22071185 / 40031184

E-mail : [contact@dileepprithvi.com](mailto:contact@dileepprithvi.com)

<https://udin.icaai.org/print-udin/2303822>

### BRANCH OFFICE :

601, Sunshine Building T-39, Opp. Mercedes Auto Hangar,  
Lokhandwala Complex Road, Shastri Nagar, Andheri (W),  
Mumbai - 400 053. • E-mail : [prithvi@dileepprithvi.com](mailto:prithvi@dileepprithvi.com)

### BRANCH OFFICE :

Office No. 1003-C, 1st Floor, World Trade Centre,  
Near Udhana Darwaja, Ring Road, Surat - 395002. (Gujarat).  
Cell : +91 77679 88047 • E-mail : [nikhil@dileepprithvi.com](mailto:nikhil@dileepprithvi.com)